FDA Cites Lupin For Poor Quality Metric Performance

Indian firm's invalidated out-of-specification rate was too high, FDA suggests in heavily redacted Form 483 report. This rate, which also came up in two recent warning letters, happens to be one of the three rates the USagency wants to use as quality metrics for deciding how soon investigators should revisit sites.

FDA has cited a manufacturer in India for performing poorly on one of the three metrics the agency has proposed to use in rating the quality of drug manufacturing facilities.

This suggests that even if industry forces FDA to delay its quality metrics initiative, the agency nevertheless can and will...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Compliance

More from Pink Sheet